Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.

Frontal fibrosing alopecia mainly affects women over 50, causing hair loss and specific skin changes.

Steroids may not work well for alopecia areata because of high unoccupied receptors and low thioredoxin levels.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

Thyroid receptor β can help develop new drugs to treat hair loss.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

Eosinophilic infiltrate is not a reliable indicator for diagnosing chronic alopecia areata.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Blocking IL-17 might help treat the hair loss condition Lichen planopilaris.

Fat tissue transplant may be an effective new treatment for severe, treatment-resistant hair loss from folliculitis decalvans.

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

The conclusion is that FFA and LPP have similar scalp biopsy features, making them hard to distinguish histologically, and FFA may be a specific kind of scarring hair loss.

Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.

D-OCT shows increased blood vessel growth in response to tissue damage in Frontal Fibrosing Alopecia and is useful for diagnosis and monitoring.

People with alopecia areata are more likely to have thyroid autoimmunity, but not thyroid disease.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Aggressive SLE treatment helped hair regrowth and improved oral plaque, but scalp lesions stayed.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.

Treatments for Frontal Fibrosing Alopecia have not been proven effective.

Some hair loss drugs can cause a unique type of hair loss that resembles both psoriasis and alopecia.

Follicular transplantation can greatly improve hair restoration if done with detailed planning and patient evaluation.

The man's occipital hair loss was due to temporal triangular alopecia, not alopecia areata.

Temporal triangular alopecia is a non-scarring hair loss in children, often linked to other health conditions.

ITK inhibitors may effectively treat alopecia areata.